Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1

NCT00309062 is registered in ClinicalTrials.gov with Allergopharma GmbH & Co. KG as lead sponsor.

NCT NCT00309062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00309062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1
Lead sponsor
Allergopharma GmbH & Co. KG
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
June 30, 2009
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

birch pollen allergy